Table 3. Univariate analysis and multivariate analysis of the correlation of the expression of CDC20, UBE2C, WDR62, DTL, HOXB4 and TRIM38 with OS among glioma patients.

Parameter	Univariate analysis			Multivariate analysis
	HR	95% CI	P	HR	95% CI	P
Age (Increasing years)	1.082	1.067−1.097	2.12E-29	1.054	1.037−1.071	2.94E-10
Gender (Male vs female)	0.932	0.664−1.308	0.685	0.949	0.653−1.379	0.785
Grade (Increasing tumor grade)	4.957	3.734−6.582	1.76E-28	1.357	0.907−2.030	0.137
Histology (oligodendroglioma vs oligoastrocytoma vs glioblastoma vs astrocytoma)	0.733	0.640−0.839	6.89E-06	0.868	0.701−1.075	0.194
Mutation Count (Increasing number)	1.000	0.999−1.000	0.346	0.997	0.988−1.007	0.531
IDH status (Mutation vs wild)	0.100	0.068−0.145	4.17E-33	0.126	0.045−0.352	7.84E-05
lp/19q co-deletion (Yes vs no)	0.223	0.126−0.396	2.91E-07	1.339	0.404−4.431	0.633
MGMT promoter status (Methylated vs unmethylated)	0.337	0.238−0.479	1.20E-09	1.166	0.755−1.801	0.487
Chr 7 gain/Chr 10 loss (Yes vs no)	8.978	6.041−13.342	1.81E-27	0.964	0.586−1.584	0.885
Chr 19/20 co-gain (Yes vs no)	3.123	1.673−5.830	0.000	0.428	0.209−0.877	0.020
ATRX status (Mutation vs wild)	0.478	0.324−0.705	0.000	1.924	0.772−4.796	0.160
CDC20 (lncreasing number)	6.535	4.480−9.534	2.01E-22	1.637	0.440−6.087	0.462
UBE2C (Increasing number)	4.257	3.006−6.026	3.21E-16	1.677	0.685−4.107	0.258
WDR62 (Increasing number)	4.852	3.344−7.040	9.17E-17	0.932	0.391−2.224	0.874
DTL (Increasing number)	4.326	2.906−6.440	5.42E-13	0.642	0.213−1.930	0.430
HOXB4 (Increasing number)	1.318	1.188−1.463	2.09E-07	1.028	0.952−1.109	0.481
TRIM38 (Increasing number)	10.441	5.495−19.838	7.92E-13	1.223	0.542−2.756	0.628

Bold values indicate P<0.05. HR, hazard ratio; OS, overall survival; CI, confidence interval.